HC Wainwright Cuts Structure Therapeutics (NASDAQ:GPCR) Price Target to $100.00

Structure Therapeutics (NASDAQ:GPCR) had its target price cut by HC Wainwright from $114.00 to $100.00 in a report issued on Monday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Structure Therapeutics’ FY2027 earnings at ($2.27) EPS, FY2028 earnings at ($2.37) EPS, FY2029 earnings at ($2.46) EPS and FY2030 earnings at ($2.25) EPS.

A number of other analysts also recently issued reports on GPCR. Leerink Partners reiterated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday. Guggenheim raised their target price on shares of Structure Therapeutics from $90.00 to $140.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. Stifel Nicolaus lifted their target price on shares of Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, December 8th. JPMorgan Chase & Co. boosted their price target on shares of Structure Therapeutics from $65.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, January 22nd. Finally, Morgan Stanley increased their price target on shares of Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $110.00.

Structure Therapeutics Stock Performance

Shares of GPCR stock opened at $51.89 on Monday. The company has a market capitalization of $3.68 billion, a PE ratio of -65.68 and a beta of -1.80. Structure Therapeutics has a 52-week low of $13.22 and a 52-week high of $94.90. The business’s fifty day moving average is $72.90 and its 200 day moving average is $50.25.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.14). On average, sell-side analysts forecast that Structure Therapeutics will post -0.82 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. State of Wyoming purchased a new position in shares of Structure Therapeutics during the second quarter worth approximately $28,000. EverSource Wealth Advisors LLC boosted its stake in shares of Structure Therapeutics by 530.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after purchasing an additional 901 shares in the last quarter. CWM LLC grew its holdings in shares of Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 125 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Structure Therapeutics by 29.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after purchasing an additional 994 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd raised its position in Structure Therapeutics by 39.1% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after purchasing an additional 1,146 shares during the period. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.